GENMAB AS SP.ADR/1/10DK 1 (GE91) — Cash Flow Reinvestment Rate
GENMAB AS SP.ADR/1/10DK 1 (GE91) has a Cash Flow Reinvestment Rate of 5.54x as of December 2025, reinvesting €1.67 Billion (capex €13.00 Million plus investments €1.66 Billion) from operating cash flow of €301.00 Million. See GE91 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
GENMAB AS SP.ADR/1/10DK 1 Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for GENMAB AS SP.ADR/1/10DK 1 across 5 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of GENMAB AS SP.ADR/1/10DK 1.
Annual Cash Flow Reinvestment Rate for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
Year-by-year capital reinvestment analysis for GENMAB AS SP.ADR/1/10DK 1. See financial flexibility index of GENMAB AS SP.ADR/1/10DK 1 to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.42x | €1.68 Billion | €1.19 Billion | €55.00 Million | ▲ +274.0% |
| 2024 | 0.38x | €411.16 Million | €1.08 Billion | €42.41 Million | ▲ +118.3% |
| 2023 | 0.17x | €190.34 Million | €1.10 Billion | €55.83 Million | ▼ -75.4% |
| 2022 | 0.71x | €397.39 Million | €563.05 Million | €45.63 Million | ▲ +63.6% |
| 2021 | 0.43x | €146.30 Million | €339.18 Million | €38.36 Million | — |